STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

CG Oncology Insider Sale: 35,441 Shares Planned on NASDAQ Sept. 18, 2025

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

CG Oncology, Inc. (CGON) filed a Form 144 reporting a proposed sale of 35,441 common shares with an aggregate market value of $1,336,834.52. The notice lists Morgan Stanley Smith Barney LLC as the broker and identifies the approximate sale date as 09/18/2025 on NASDAQ. The shares were recorded as acquired on 09/18/2025 through an exercise of stock options, paid in cash. The filing also discloses a prior Rule 10b5-1 sale by James J. Mulay of 27,015 shares on 09/05/2025 for gross proceeds of $851,759.01. The filer represents no undisclosed material adverse information.

Positive

  • Full disclosure of proposed sale including broker, quantity, value, and approximate sale date
  • Acquisition and payment details provided (exercise of stock options on 09/18/2025 paid in cash)
  • Prior 10b5-1 sale disclosed showing use of a structured trading plan and transparency

Negative

  • Insider is proposing to sell shares, which may be interpreted by some investors as a liquidity event
  • Filing contains no operational or financial performance data to provide context for the sale

Insights

TL;DR: Insider option exercise and proposed sale are disclosed; transaction size is modest relative to outstanding shares.

The filing shows an insider exercising options and proposing to sell 35,441 shares valued at $1.34 million, against 76,247,581 shares outstanding, which represents a small fraction of the company's capitalization. The disclosure is routine and follows SEC Rule 144 procedures. The recent 10b5-1 sale of 27,015 shares for $851,759.01 indicates prior liquidity activity by an insider. There are no earnings or operational metrics in this filing to assess company performance.

TL;DR: Proper insider sale disclosures and 10b5-1 plan usage are evident; no governance red flags are stated.

The Form 144 provides required broker, acquisition, and sale-date information and includes the signature attestation about material nonpublic information. The use of a broker and prior 10b5-1 sales suggests adherence to structured trading protocols. The filing does not disclose any material nonpublic information or governance issues; therefore, from a disclosure-compliance perspective, the document appears complete for the transaction reported.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the CGON Form 144 report?

The filing reports a proposed sale of 35,441 common shares valued at $1,336,834.52, to be executed approximately on 09/18/2025 via Morgan Stanley Smith Barney LLC.

How were the shares acquired that are being sold in the CGON filing?

The shares were acquired on 09/18/2025 through an exercise of stock options and paid for in cash.

Has any insider sold CGON shares recently?

Yes. A Rule 10b5-1 sale by James J. Mulay of 27,015 shares occurred on 09/05/2025 for gross proceeds of $851,759.01.

On which exchange will the CGON shares be sold?

The proposed sale is listed for execution on NASDAQ.

How large is the proposed sale relative to outstanding shares of CGON?

The proposed 35,441 shares are reported against 76,247,581 shares outstanding in the filing.
CG Oncology, Inc.

NASDAQ:CGON

CGON Rankings

CGON Latest News

CGON Latest SEC Filings

CGON Stock Data

3.44B
73.31M
1.17%
112.6%
13.42%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
IRVINE